Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GeneReach BiotechnologyROCO:4171 58 Days Payable is 24.21 as of Jun. 2026, which is 53% above its 10-year median of 15.87. GuruFocus rates ROCO:4171 with a GF Score™ of 58/100 and a GF Value™ of NT$26.12 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 709 Biotechnology companies, GeneReach Biotechnology ranks worse than 95.2% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4171 vs VRTX, REGN, MRNA: Days Payable Comparison
For the Biotechnology subindustry, GeneReach Biotechnology's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GeneReach Biotechnology Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, GeneReach Biotechnology's Days Payable distribution charts can be found below:
* The bar in red indicates where GeneReach Biotechnology's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
GeneReach Biotechnology's Days Payable for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GeneReach Biotechnology (ROCO:4171) has a Days Payable of 24.21 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on GeneReach Biotechnology and its competitors. This is 53% above median its historical median of 15.87. Over the past decade, GeneReach Biotechnology's Days Payable has ranged from 1.27 to 41.98. According to the industry distribution chart, GeneReach Biotechnology ranks #675 out of 709 companies in the Biotechnology industry, placing it in the top 95.2%.
Is GeneReach Biotechnology's Days Payable too high?
GeneReach Biotechnology's current Days Payable of 24.21 is 53% above median its 10-year median of 15.87. Over the past 10 years, this metric has ranged from a low of 1.27 to a high of 41.98. The Biotechnology industry median Days Payable is 111.24. GeneReach Biotechnology's value of 24.21 is 78.2% below this industry median. Based on the distribution chart, GeneReach Biotechnology ranks #675 out of 709 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, GeneReach Biotechnology has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does GeneReach Biotechnology's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, GeneReach Biotechnology ranks #675 out of 709 companies for Days Payable. This places GeneReach Biotechnology in the lower half of its industry. The industry median Days Payable is 111.24. GeneReach Biotechnology's value of 24.21 is 78.2% below this benchmark. Historically, GeneReach Biotechnology's own Days Payable has ranged from 1.27 to 41.98 over the past decade. While the company's 10-year median is 15.87 vs. the industry median of 111.24, GeneReach Biotechnology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 111.24, based on 709 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GeneReach Biotechnology's current Days Payable of 24.21 is 78.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on GeneReach Biotechnology and its competitors. For the Biotechnology industry, the median Days Payable is 111.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GeneReach Biotechnology's current Days Payable is 24.21, which is 53% above median its own 10-year median of 15.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GeneReach Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, GeneReach Biotechnology (ROCO:4171) is currently considered Possible Value Trap. The stock's GF Value™ is NT$26.12, compared to a current price of NT$16.80 — trading 35.7% below its estimated fair value. The current Days Payable is 24.21, which is 53% above median its 10-year median of 15.87 and 78.2% below the Biotechnology industry median of 111.24. GeneReach Biotechnology's overall GF Score™ is 58/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For GeneReach Biotechnology (ROCO:4171), the current Days Payable is 24.21 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GeneReach Biotechnology (ROCO:4171) Overvalued in 2026?
Based on GuruFocus' analysis, GeneReach Biotechnology stock appears to be undervalued.
The current stock price of NT$16.80 is trading 35.7% below its estimated GF Value™ of NT$26.12.
GuruFocus considers GeneReach Biotechnology to be Possible Value Trap.
Key valuation signals for ROCO:4171:
Days Payable: 24.21 (53% above median its 10-year median of 15.87)
GF Value™: NT$26.12 vs. price of NT$16.80 (35.7% below fair value)
Industry Position: 78.2% below the Biotechnology median (#675 of 709)
No single metric tells the full story. See the ROCO:4171 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GeneReach Biotechnology Corp is a biotechnology company. The company develops, manufactures and markets products for applied nucleic acid detection technology. Its products are utilised for aquaculture, agriculture, food, companion animal, livestock and human health industries.
58GF Score
Get the complete analysis for ROCO:4171
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4171 has been successfully added to your 
